Cases of Clostridioides difficile (C. difficile) infection are increasing throughout the United States, causing a current healthcare crisis. An extensive, nationwide health insurance database analysis by the University of Pennsylvania determined that acute C. difficile infections’ annual incidence increased by almost two hundred percent from 2001 to 2012. “C. difficile causes over 500,000 infections per year in the United States alone, resulting in an estimated 29,000 deaths and an estimated cost of $1–3 billion.” There are many different contributing factors to why there is such an alarming increase in C. difficile infections. Overuse of antibiotics which weaken our normal probiotic flora that keeps the bacteria in check and proximity to multitudes of people within hospitals, mixing our microbiomes are significant causes of the increase in infection rate. Remember, our probiotic microbiome produces many different bactericides and stimulates our immune system to reduce or eliminate the pathogens that we come in contact within our everyday lives. C. difficile is being discussed as a potential pathogen that can be acquired as a foodborne illness as well since it can infect pigs and cattle that we ingest and can be found in commercially tested meat. The bacteria have also been found in improperly treated drinking water and raw sewage. C. difficile dysbiosis can be challenging to remedy; many people spend weeks or months in the hospital trying to recover from an infection. So what is causing the increase in C. difficile dysbiosis, and what can be done to keep people from getting it as often? In addition, what protocol’s can someone follow to relieve C. difficile dysbiosis?1 2 3 4

All About Clostridioides difficile

Clostridioides difficile is an opportunistic Gram-positive bacteria that is generally found within the microbiome of at least two to five percent of the adult population. The bacteria was first called Bacillus difficilis by Ivan C. Hall and Elizabeth O’Toole in 1935. The bacteria was named difficilis because it was difficult to isolate and grew very slowly within the culture medium. André Romain Prévot eventually transferred it to the genus Clostridium, where it became commonly known as Clostridium difficile. It has recently been changed again to Clostridiodes difficile after being transferred to the new genus Clostridioides. Clostridioides are anaerobic (does not like oxygen), motile bacteria, ubiquitous in nature. C. diff forms unique endospores that are rod-shaped produce biofilm, produce toxins, and are found within soil.5 6 7 8 9

C. diff produces two toxins when they are vegetative cells and not encapsulated in endospores that can cause significant health issues, including Clostridioides difficile toxin A and Clostridioides difficile toxin B. TcdA gene encodes C. diff toxin A and TcdB gene encodes C. diff toxin B. The toxins also are capable of reducing or eliminating some organisms within our native flora as well. Both toxins bind to specific host cell receptors within the digestive tract, which the toxins then enter the cell and induce cytopathic and cytotoxic effects. Since both toxins increase cellular oxidative stress and trigger premature cell death, they can cause inflammation (increase in immune function and cytokine production in response to the toxins) and cellular destruction within the colon, leading to colitis and within the small intestine leading to ileitis, for example which is sometimes severe. Finally, if the toxins enter into the bloodstream from someone having a “leaky gut” they can cause toxemia, heart, kidney, and brain inflammation and damage.10 11

Endospores (not a true spore) are dormant Gram-positive bacteria generally from the Firmicutes phylum. The endospores are tough encapsulations that protect spore-forming bacteria from your immune system, antibiotics, antibacterials, and your microbiome. Spore-forming bacteria can lay dormant in endospore form until their environment becomes favorable for faster reproduction and survival. Spore-forming bacteria form endospores when there is a lack of nutrients and can survive a long time until they get the nutrients they need to survive (the amino acids l-alanine, l-valine, l-asparagine, glycine, and fructose are some of those nutrients); they will germinate and multiply. Clostridioides difficile are resistant to stomach acid, but interestingly stomach acid-reducing medications including H2 antagonists and proton pump inhibitors, have been linked to increasing the risk C. difficile dysbiosis. Researchers believe it is because they interfere with normal gastrointestinal microbial diversity. People on these medications long term seem to suffer from dysbiosis, which allows C. difficile to thrive because of a lack of a probiotic microbiome. Endospores are likely to germinate within the colon from repeated exposure (if enough colony-forming units are ingested) or supplementation. The bacteria may also share a commensal relationship with probiotic bacteria for a time and continue to replicate when nutrients are available. Bacterial endospores are resistant to ultraviolet radiation, desiccation, many antibiotics, boiling, extreme freezing, and most chemical disinfectants. For example, bacteria in the Clostridia class are spore-forming; it becomes difficult to eliminate them if they become opportunistic and return to their spore form.12 13 14 15

Clostridioides difficile germinates when exposed to bile (unlike other endospore bacteria that are a part of the Bacillus genus for example that perish when exposed to bile) or glycine within the small intestine. Once C. diff germinates, it attempts to colonize the large intestine (a perfect anaerobic environment for it). Usually, our immune system and our microbiome keep C. diff in check so that it does not have the opportunity to become opportunistic and our digestive tract eliminates it through our stool. However, if our immune system is hindered or our gut flora is severely disrupted (taking antibiotics for example), C. diff either colonizes or if it is already native flora germinates and causes dysbiosis and infection.”Because C. difficile is an obligate anaerobic pathogen, the vegetative cells are unable to survive outside of a host in the aerobic environment. When C. difficile cells meet certain environmental stimuli (e.g., nutrient deprivation, quorum sensing, and other unidentified stress factors), they will initiate a sporulation pathway to produce sufficient dormant spores to survive in extreme situations. C. difficile pathogenesis relies on the formation of aerotolerant dormant spores which allows C. difficile to persist within the host and to disseminate through patient-to-patient contact/environmental contamination. In the host GI tract, the dormant spores must germinate from dormancy to form the actively growing vegetative cells which produce the toxins that cause the primary symptoms of the disease. Under suitable conditions, when germinant receptors sense the presence of small molecules (germinants), spore germination will be induced.16

Though C. diff dysbiosis is generally found within the large intestine, it can be found within the small intestine. There are many reported cases of it being able to colonize the ileum. It is unknown how far within the upper gut C. diff can colonize. Still, it appears that in most cases, it can inhabit no farther than the small intestine (the rest of the upper digestive tract, like the stomach, is exposed to more oxygen from swallowing food, which can kill C. diff). One of the appendix functions is to be a “safe house” for probiotic flora to colonize after a foodborne illness. In a study conducted in 2011, when C. difficile were introduced into the gut, the appendix housed cells that increased the body’s antibody response to eliminate it. The appendix’s B cells stimulate toxin A-specific IgA and IgG antibody production, leading to an increased probability of probiotic flora surviving and overcoming C. difficile. Finally, here is a conclusion from a study discussing C. diff small intestine colonization:Small intestinal C. difficile seems to be increasing in incidence. The spectrum of CDI has definitely expanded with small bowel involvement. Heightened public awareness and initiation of prompt preventive measures are the keystones to control of this infection. This disease is no longer limited to the colon and physicians should be educated to think beyond the colon in patients with CDI.17 18 19

How to Properly Diagnose and the Symptoms of Clostridioides difficile Dysbiosis and Infection

Symptoms of an acute Clostridioides difficile infection and dysbiosis include severe diarrhea (makes up 20% of cases of antibiotic-resistant diarrhea), abdominal pain, fever, nausea, vomiting, colitis, ileitis, malabsorption, bloating, abdominal distension, weight loss, small intestinal bacterial overgrowth, colonic overgrowth, and a distinctive foul stool odor. If you have these symptoms and have had recent antibiotic therapy (clindamycin (highest known risk of all antibiotics), fluoroquinolones, cephalosporins, aztreonam, carbapenems, macrolides, sulfonamides/trimethoprim, and penicillins all have increased risks of causing C. difficile dysbiosis), use of acid-reducing medication including H2 antagonists and proton pump inhibitors, compromised immune system, recent abdominal surgery, prior appendectomy, or recent hospitalization then it is likely you have a C. difficile infection. Finally, many gastroenterologists are unaware that C. difficile in cases of chronic dysbiosis and severe infection can cause constipation instead of diarrhea, sometimes quite severe.20 21 22 23 24

Clostridioides difficile dysbiosis in some instances can cause a “reconstruction“, swelling, and extreme inflammation of the colon, a medical condition known as pseudomembranous colitis. Exogenous “mucous membranes” (very intricate biofilm colonies) are produced by C. difficile, further protecting it from your immune system, probiotic flora, and antimicrobial agents and causing severe colitis. If your C. difficile infection is severe, it can cause a condition known as toxic megacolon, a life-threatening medical condition where the colon swells considerably and hemorrhages, causing blood loss and perforations (holes within the intestinal tract where organisms can enter the bloodstream and surrounding organs) causing sepsis.25 26

Clostridioides difficile is generally diagnosed through symptomology, medical history, ELISA tests for C. difficile toxins A and B (make sure both are tested), culture and biopsy during colonoscopies or endoscopies, and diagnostic scanning, including abdominal X-ray or computed tomography (CT) scan with contrast (I would recommend supplementing with iodine if possible before the CT scan with contrast and afterward if they use Iodine-131 to protect your thyroid) to determine the health of your digestive tract and the extent of the infection. Remember, if you test positive for the C. difficile toxins, have elevated Clostridium in stool testing, and have many of the above symptoms, then C. difficile dysbiosis might be the cause of your digestive issues, even if you are suffering from chronic constipation.27 28

Clostridioides difficile is resistant to many antibiotics, creates biofilms, and can form endospores to survive treatment which makes it very difficult to recover and has a recurrence rate of around twenty percent. C. difficile infections are severe, and in most cases, are treated at a hospital. There are supplements and lifestyle changes that may help prevent the infection from occurring when you are hospitalized. If you are hospitalized or are on strong antibiotics for an extended period, supplementation of the probiotic supplement Smidge (taken separately during the day from the antibiotics) should be considered to help prevent opportunistic C. difficile infection. One or two servings daily of fermented food ingestion or kombucha, when ingested away from your antibiotic, may help as well. You can also supplement with thirty milligrams of exposure, and doing your best to maintain proper sleep hygiene can help as well. Excessive dietary or supplementation of calcium can also stimulate C. difficile’s germination. I would also refrain from ingesting foods that contain more glycine including protein powders or collagen, large amounts of dietary fructose, or trehalose (a sugar that is found in honey) because they can improve C. difficile’s chances of colonization of virulence. Proper handwashing (I do not recommend conventional antibacterial soap) can help reduce your chances of contracting C. difficile’s. Hand sanitizer can work against germinated C. difficile’s but does nothing to eliminate C. difficile’s spores; proper hand washing is always superior. Finally, I would avoid iron-fortified foods and carrageenan, which cause gut inflammation and try to follow the Perfect Health Diet if possible.29 30 31 32 33 34 35 36 37

Finally, I generally do not recommend fecal microbiome transplantation because I have read a multitude of studies and anecdotal evidence and coached many people that have had it done with minimal positive results especially in people with chronic dysbiosis. However, since Clostridioides difficile primarily colonizes the colon (where fecal microbiome transplantation appears to work best) and fecal microbiome transplantation for C. difficile is backed by research from many studies and reports of anecdotal evidence, it appears that the appropriate use of fecal microbiome transplantation might be highly effective in people suffering from C. difficile dysbiosis and infection. Fecal microbiome transplantation for C. difficile should be considered when all other options have failed to relieve the dysbiosis.38 39

Clostridioides difficile Dysbiosis Protocol

Medication Recommendations

  • If your C. difficile dysbiosis is in the small intestine, I recommend the use of the antibiotic rifaximin – take as directed (push for the use of rifaximin if possible, it has been shown through multiple studies that it can help eliminate C. difficile with fewer side effects then metronidazole (Flagyl) or vancomycin).40 41 42
  • Nitazoxanide (Alinia)– an antibacterial, antiarchaeal, antiparasitical, antiviral medication that works well against C. difficile. Nitazoxanide has average antimicrobial side effects associated with its use, including stomach pain, headache, upset stomach, vomiting, discolored urine, excessive urinating, skin rashes, itching, fever, Herxheimer reactions, and rare systemic allergic reactions. Since it binds with plasma proteins, it can increase drug toxicity for other drugs with high plasma binding affinity, including warfarin. Finally, nitazoxanide does not appear to affect the CYP450 system. Therefore nitazoxanide should not interfere with most medications that require CYP450 proteins for metabolism unless they have high plasma binding affinity.43
  • Chenodeoxycholic acid – a bile acid that is effective in inhibiting C. difficile germination. Side effects include allergic reactions, dark urine, constipation, diarrhea, heartburn, reflux, upset stomach, gastritis, bloating, fatigue, loss of appetite, nausea, vomiting, and jaundice. Rarely it can cause liver damage, so have your liver enzymes monitored during use and try to use the lowest therapeutic dose possible. Do not use it if you have gallstones in your bile duct.44 45 46
  • Cholestyramine (Questran) – a medication that binds with both bile and C. difficile toxins. Since cholestyramine binds with bile, it may inhibit C. difficile germination. Use with caution if you are suffering from hypothyroidism since it may worsen the medical condition. It can cause constipation and rarely bile obstruction. Finally, do not take cholestyramine at the same time as chenodeoxycholic acid it will bind to it, rendering it ineffective.47 48
  • If you cannot use rifaximin (Xifaxan), fidaxomicin, or nitazoxanide (Alinia), then I would recommend the use of metronidazole (Flagyl) instead of vancomycin if at all possible. Vancomycin is bacteriostatic and inhibits the growth of C. difficile but does not outright kill it like fidaxomicin. Vancomycin, in my opinion, should always be used as a last resort because of the risk of side effects associated with it.49

Anti-Biofilm and Anti-Endospore Protocol

  • InterFase plus (use if you do not have any mercury amalgams or are mercury burdened; if you are, then use InterFase instead) consists of two capsules between breakfast and lunch and two capsules between lunch and dinner. If needed, take two more capsules one hour before bedtime. You must take InterFase Plus on an empty stomach.
  • Lactoferrin consists of one thousand to three thousand milligrams daily in divided doses with meals.50

Protocol Recommendations and Supplements

If symptoms have not improved on an antibiotic or natural methods are used to treat C. difficile dysbiosis, then the following antimicrobial agents are effective against C. difficile. I recommend that you talk to your healthcare professional about choosing two or three antimicrobial agents and rotating them with new antimicrobial agents every few weeks until you recover:

  • Nature’s Way enteric-coated peppermint oil – thirty to sixty minutes before meals, twice daily. Recommended if you are suffering from diarrhea only.51
  • Thorne Research berberine – take five hundred milligrams, twice daily with meals. You can take up to three thousand milligrams daily with meals, but discontinue if berberine causes hypoglycemia or gastritis.52
  • Allicin – one capsule with breakfast and one with dinner. Use with caution if you are suffering from hydrogen sulfide dysbiosis or have CBS polymorphisms.53
  • Thorne Meriva curcumin takes one to four capsules total daily in divided doses with meals and reduces intestinal inflammation.54
  • Ceylon cinnamon oil – works well in combination with other agents since it is bacteriostatic and hinders the growth of C. difficile but does not kill it. It also does not broadly affect the probiotic microbiome, especially probiotic Gram-negative bacteria. Mix one or two drops in with 1/2 teaspoon of extra virgin coconut oil and taken with breakfast and dinner.55

I generally do not recommend the use of the following antimicrobials unless C. difficile dysbiosis is severe since they can strongly impact the probiotic microbiome:

  • Zane Hellas oil of oregano – potent, broad-spectrum, systemic antimicrobial agent. One to two soft gels with breakfast and one to two soft gels with dinner.56

Lifestyle changes and supplements that may help you recover from C. difficile dysbiosis

  • Proper sunlight exposure and proper sleep hygiene are essential for healthy immune function.
  • Proper vitamin D endogenous production is crucial for immune function.
  • Avoid ingestion of trehalose and honey, although manuka honey might be ok due to its elevated amounts of antimicrobial agents, including methylglyoxal. Also, avoid mushrooms and algae, which have a good amount of trehalose.
  • Avoid ingesting a lot of fruit because they contain fructose. Ingestion of low fructose fruits, including berries, on occasion, is acceptable.
  • Avoid ingestion of supplemental glycine or products that contain elevated amounts of glycine, including collagen.
  • Avoid ingestion of bile acid supplements, Jarrow Bile Factors, for example. Activated charcoal supplementation used between meals might absorb bile acids within the small intestine and hinder C. difficile germination and help bind and eliminate C. difficile toxins.
  • Avoid ingestion of foods that trigger excessive bile release, including oleic acid (olives, avocados), food, and meals that are high in fat, ginger, spicy food, coffee, and potatoes.
  • Talk to your healthcare professional about discontinuing any stomach acid-reducing medications you are on. Consider supplementing with betaine HCL if you have elevated stomach pH.
  • Nutribiotic Sodium Ascorbate – take a total of four thousand milligrams daily in divided doses with meals.
  • Rosita cod liver oil soft gels – take four soft gels total daily in divided doses with meals.
  • Pure Encapsulations Magnesium (glycinate) – take four hundred milligrams daily before bed.
  • S. boulardii probiotic – take while you have active C. difficile dysbiosis or infection as long as you do not suffer from yeast sensitivity or Th2 dominance (histamine intolerance).
  • E. coli Nissle probiotic – take while you have active C. difficile dysbiosis or infection.
  • Supplementation of the prebiotic supplement Holigos might help improve your probiotic microbiome during C. difficile dysbiosis.

Fructose, glycine, and trehalose feed C. difficile and allow it to grow and become more virulent.

C. difficile requires bile to germinate.

Ascorbate, omega three oils, and magnesium reduce intestinal inflammation and improve outcomes.

C. boulardii and E. coli Nissle compete with C. difficile and can help to reduce it.

If Clostridioides difficile dysbiosis infection worsens or frequently reoccurs, consider fecal matter transplant.

  1. https://www.pennmedicine.org/news/news-releases/2017/june/cases-of-recurrent-clostridium-difficile-infection-are-soaring
  2. Poter, S. Robert. The Merck Manual, Merck; 19 edition, July 20, 2011
  3. https://academic.oup.com/cid/article/51/5/577/334288
  4. https://www.ncbi.nlm.nih.gov/pubmed/23503193
  5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935936/
  6. Bauman, Robert. Microbiology with Diseases by Body System, Benjamin Cummins, September 12, 2012
  7. https://www.semanticscholar.org/paper/Clostridioides-difficile-Biology%3A-Sporulation%2C-and-Zhu-Sorg/cecbf880507eb9eabc1239ee6ab896bbd76b9dc8
  8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871928/
  9. https://www.ncbi.nlm.nih.gov/pubmed/27370902
  10. https://www.semanticscholar.org/paper/Clostridioides-difficile-Biology%3A-Sporulation%2C-and-Zhu-Sorg/cecbf880507eb9eabc1239ee6ab896bbd76b9dc8
  11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885049/
  12. https://www.semanticscholar.org/paper/Clostridioides-difficile-Biology%3A-Sporulation%2C-and-Zhu-Sorg/cecbf880507eb9eabc1239ee6ab896bbd76b9dc8
  13. Bauman, Robert. Microbiology with Diseases by Body System, Benjamin Cummins, September 12, 2012
  14. Poter, S. Robert. The Merck Manual, Merck; 19 edition, July 20, 2011
  15. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2173095
  16. https://www.semanticscholar.org/paper/Clostridioides-difficile-Biology%3A-Sporulation%2C-and-Zhu-Sorg/cecbf880507eb9eabc1239ee6ab896bbd76b9dc8
  17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664326/
  18. https://www.liebertpub.com/doi/full/10.1089/crsi.2016.0006
  19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769896/
  20. Potter, S. Robert. The Merck Manual, Merck; 19 edition, July 20, 2011
  21. Bauman, Robert. Microbiology with Diseases by Body System, Benjamin Cummins, September 12, 2012
  22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391391/
  23. https://www.pharmacytimes.com/contributor/sean-kane-pharmd/2017/03/which-antibiotics-are-most-associated-with-causing-clostridium-difficile-diarrhea
  24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769896/
  25. Poter, S. Robert The Merck Manual, Merck; 19 edition, July 20, 2011
  26. Bauman, Robert Microbiology with Diseases by Body System, Benjamin Cummins, September 12, 2012
  27. Poter, S. Robert. The Merck Manual, Merck; 19 edition, July 20, 2011
  28. Bauman, Robert. Microbiology with Diseases by Body System, Benjamin Cummins, September 12, 2012
  29. Poter, S. Robert The Merck Manual, Merck; 19 edition, July 20, 2011
  30. Bauman, Robert. Microbiology with Diseases by Body System, Benjamin Cummins, September 12, 2012
  31. https://www.ncbi.nlm.nih.gov/pubmed/28704538
  32. https://www.ncbi.nlm.nih.gov/books/NBK144042/
  33. https://jamanetwork.com/journals/jama/article-abstract/2675907
  34. https://gut.bmj.com/content/64/5/731
  35. https://www.ncbi.nlm.nih.gov/pubmed/29070552
  36. https://www.ncbi.nlm.nih.gov/pubmed/19263912
  37. https://www.ncbi.nlm.nih.gov/pubmed/18245298
  38. https://www.ncbi.nlm.nih.gov/pubmed/28704538
  39. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441021/
  40. https://www.ncbi.nlm.nih.gov/pubmed/28704538.
  41. Fidaxomicin (Dificid) – a fermentation product obtained from the actinomycete Dactylosporangium aurantiacum subspecies hamdenesis, which is a narrow spectrum macrocyclic antibiotic. Fidaxomicin seems to be poorly absorbed into the systemic circulation (ninety-two percent is eliminated directly through deification) like rifaximin and seems to have little effect on some of our Gram-negative colonic probiotic flora. “Fidaxomicin has poor activity against aerobic and facultative gram-negative bacilli, Bacteroides species (MIC90 of >1,024 μg/ml), and other gram-negative anaerobes, a feature that might result in a reduced ecologic impact.” Fidaxomicin is effective against Gram-positive bacteria (remember some probiotic bacteria are Gram-positive, including Lactobacillus and Bifidobacteria), especially C. difficile infection and dysbiosis. Fidaxomicin binds to and prevents movement of the “switch regions” of bacterial RNA polymerase (similar to rifamycins), trapping the RNA polymerase “clamp” in the open conformation, not allowing it to close and hold onto DNA, killing the bacteria. Fidaxomicin has only been approved for use by the FDA since 2011, so more studies need to be done to prove its safety; that being said I recommend fidaxomicin over other antibiotics (other than rifaximin) that are used for the treatment of C. difficile.[41. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612159/
  42. https://www.nejm.org/doi/full/10.1056/NEJMoa0910812
  43. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926343/
  44. https://www.ncbi.nlm.nih.gov/pubmed/19133801
  45. https://jb.asm.org/content/192/19/4983
  46. https://www.allinahealth.org/CCS/doc/Thomson%20Alternative%20Medicine/48/10357.htm
  47. https://livertox.nih.gov/Chenodiol.htm
  48. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885049/
  49. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331142/
  50. Poter, S. Robert. The Merck Manual, Merck; 19 edition, July 20, 2011
  51. https://www.ncbi.nlm.nih.gov/pubmed/26759363
  52. https://www.ncbi.nlm.nih.gov/pubmed/28489336
  53. https://www.researchgate.net/publication/321493913_Berberine_hydrochloride_could_prove_to_be_a_promising_bullet_against_Clostridium_difficile_infection_A_preliminary_study_from_South_India
  54. https://www.ncbi.nlm.nih.gov/pubmed/28489336
  55. https://www.gastrojournal.org/article/S0016-5085(09)62911-5/abstract
  56. https://www.ncbi.nlm.nih.gov/pubmed/28489336
  57. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975404/